MoonLake Current Deferred Revenue from 2010 to 2024
| MLTX Stock | USD 54.43 0.19 0.35% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -166.9 K | Current Value -175.3 K | Quarterly Volatility 5.3 K |
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 K, Other Operating Expenses of 34.1 M or Total Operating Expenses of 34.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.28. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
MoonLake | Current Deferred Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.